These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15356405)

  • 1. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy.
    Dimitrakakis C; Jones RA; Liu A; Bondy CA
    Menopause; 2004; 11(5):531-5. PubMed ID: 15356405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women.
    Tamimi RM; Hankinson SE; Chen WY; Rosner B; Colditz GA
    Arch Intern Med; 2006 Jul; 166(14):1483-9. PubMed ID: 16864758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study.
    Glaser RL; Dimitrakakis C
    Maturitas; 2013 Dec; 76(4):342-9. PubMed ID: 24028858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
    Tworoger SS; Missmer SA; Barbieri RL; Willett WC; Colditz GA; Hankinson SE
    J Natl Cancer Inst; 2005 Apr; 97(8):595-602. PubMed ID: 15840882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer incidence and hormone replacement therapy in Canada.
    De P; Neutel CI; Olivotto I; Morrison H
    J Natl Cancer Inst; 2010 Oct; 102(19):1489-95. PubMed ID: 20864685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy.
    Bitzer J; Kenemans P; Mueck AO;
    Maturitas; 2008 Mar; 59(3):209-18. PubMed ID: 18343056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer risk in relation to the interval between menopause and starting hormone therapy.
    Beral V; Reeves G; Bull D; Green J;
    J Natl Cancer Inst; 2011 Feb; 103(4):296-305. PubMed ID: 21278356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incidence of invasive breast cancer among women prescribed testosterone for low libido.
    Davis SR; Wolfe R; Farrugia H; Ferdinand A; Bell RJ
    J Sex Med; 2009 Jul; 6(7):1850-6. PubMed ID: 19453875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
    Gurney EP; Nachtigall MJ; Nachtigall LE; Naftolin F
    J Steroid Biochem Mol Biol; 2014 Jul; 142():4-11. PubMed ID: 24172877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmenopausal testosterone therapy and breast cancer risk.
    Somboonporn W; Davis SR
    Maturitas; 2004 Dec; 49(4):267-75. PubMed ID: 15531122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical study of the month. Benefit/risk balance of postmenopausal estrogen-progestin treatment in peril in the Women's Health Initiative study: practical attitude of the clinician].
    Gaspard U; van den Brûle F; Pintiaux A; Foidart JM
    Rev Med Liege; 2002 Aug; 57(8):556-62. PubMed ID: 12405030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effect of oral contraceptive use and hormone replacement therapy on breast cancer risk in postmenopausal women.
    Norman SA; Berlin JA; Weber AL; Strom BL; Daling JR; Weiss LK; Marchbanks PA; Bernstein L; Voigt LF; McDonald JA; Ursin G; Liff JM; Burkman RT; Malone KE; Simon MS; Folger SG; Deapen D; Wingo PA; Spirtas R
    Cancer Causes Control; 2003 Dec; 14(10):933-43. PubMed ID: 14750532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women.
    de Lignières B; de Vathaire F; Fournier S; Urbinelli R; Allaert F; Le MG; Kuttenn F
    Climacteric; 2002 Dec; 5(4):332-40. PubMed ID: 12626212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
    Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
    Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone therapy and ovarian cancer.
    Mørch LS; Løkkegaard E; Andreasen AH; Krüger-Kjaer S; Lidegaard O
    JAMA; 2009 Jul; 302(3):298-305. PubMed ID: 19602689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
    J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidences of breast cancer throughout long-term hormone replacement therapy.
    Cortés-Prieto J; Juez-Martel P
    J Steroid Biochem Mol Biol; 2007 May; 104(3-5):180-9. PubMed ID: 17467269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
    Colditz GA; Hankinson SE; Hunter DJ; Willett WC; Manson JE; Stampfer MJ; Hennekens C; Rosner B; Speizer FE
    N Engl J Med; 1995 Jun; 332(24):1589-93. PubMed ID: 7753136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.
    Kerlikowske K; Miglioretti DL; Ballard-Barbash R; Weaver DL; Buist DS; Barlow WE; Cutter G; Geller BM; Yankaskas B; Taplin SH; Carney PA
    J Clin Oncol; 2003 Dec; 21(23):4314-21. PubMed ID: 14645420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
    Nozaki M; Koera K; Nagata H; Nakano H
    J Obstet Gynaecol Res; 2004 Aug; 30(4):297-302. PubMed ID: 15238106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.